{"schema_version":"secwatch.filing_event.v1","accession":"0001831283-23-000145","form_type":"8-K","ticker":"LIANY","cik":"0001831283","company_name":"LianBio","filed_at":"2023-12-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.843478+00:00","generated_at":"2026-06-07T07:31:38.529154+00:00","sec_items":["1.01","1.02"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LianBio sells NBTXR3 rights in Asia to Janssen for $25M upfront plus potential $5M milestone","bullets":["Asset Purchase Agreement with Janssen (Johnson & Johnson) executed Dec 22, 2023.","LianBio receives $25 million one-time payment at closing.","Eligible for $5 million milestone if annual net sales in PRC exceed $20 million.","Transition activities to be completed within six months post-closing.","Concurrent Novation Agreement with Nanobiotix consenting to the deal."],"urls":{"canonical":"https://secwatch.observer/filing/0001831283-23-000145","json":"https://secwatch.observer/filing/0001831283-23-000145.json","markdown":"https://secwatch.observer/filing/0001831283-23-000145.md","text":"https://secwatch.observer/filing/0001831283-23-000145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/lian-20231222.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T07:31:38.529154+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6cf25004fdfb5beec93ba10f9eba89df4c413154","claim":"LianBio terminated License, Development and Commercialization Agreement with Nanobiotix S.A..","evidence_excerpt":"Item 1.02 Termination of a Material Definitive Agreement. The disclosures regarding the Transactions set forth in Item 1.01 above are incorporated by reference into this Item 1.02.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm","confidence":0.7,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"Nanobiotix S.A."}],"fact_type":"material_agreement"},{"claim_id":"df6d69c74b11e58590d6f8f8714a4673111ff753","claim":"LianBio entered into Asset Purchase Agreement with Janssen Pharmaceutica NV valued at $25 million (effective 2023-12-22).","evidence_excerpt":"On December 22, 2023 (the “Closing Date”), LianBio Development (HK) Limited (“LianBio Development”), a subsidiary of LianBio, Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, and, as applicable, LianBio entered into an Asset Purchase Agreement (the “APA”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1831283/000183128323000145/0001831283-23-000145-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"asset purchase"},{"label":"Counterparty","value":"Janssen Pharmaceutica NV"},{"label":"Value","value":"$25 million"},{"label":"Effective","value":"2023-12-22"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}